US Restricts Use of GSK/Vir’s Xevudy, Deemed ‘Unlikely’ To Help Against Rising Omicron Variant
Lilly And AstraZeneca Antibodies Retain Potency
The US government has bought around $1.9bn worth of Xevudy so far, but further sales are in jeopardy following the results in BA.2. • Source: Alamy 
